Skip to content

Discovery Highlights

In addition to exploring science by testing molecules in our disease-relevant assays, we also seek specific partnerships and collaborations.
We are now using PPI (protein-protein interaction) technology to produce the next class of small molecules that work like biologics but can be delivered orally for patients with inflammatory skin diseases who prefer to avoid injectable treatments. 
We are currently exploring partnerships related to PPI technologies using our two specific assays targeting the IL4-Receptor and STAT6.

We invite you test your molecules for the ability to inhibit the protein-protein interactions of those targets and look for other opportunities highlighted below.

Protein-Protein Interactions

We are now using PPI (protein-protein interaction) technology to produce the next class of small molecules that work like biologics but can be delivered orally for patients with inflammatory skin diseases. Explore collaboration opportunities by testing your PPI modulators for IL4R or STAT6.

PPI inhibitors

New Drug Targets

We continuously look for new drug targets for future medical treatments of inflammatory skin diseases and would like you to be part of this. We would love to hear about your protein, target or biological mechanism that could be explored and validated as a potential future drug target.

New Drug Targets

The Next Big Thing

More information to come.

Scroll to top